Posts Tagged 'Pradaxa'

Pradaxa Linked with Increased Risk of Gastrointestinal Bleeding

A new study shows the use of the anti-coagulant known as Pradaxa is associated with a significant increase in the risk of gastrointestinal bleeding. The increased risk is compared to traditional or standard treatment with drugs such as enoxaparin, warfarin, antiplatelet therapy, or no therapy (placebo).

The study analyzed 17 randomized controlled trails and found an increased risk for gastrointestinal bleeding for patients taking newer anti-coagulants versus the more traditional treatments. Although there was a significant ...

continue reading...

Number of Pradaxa Lawsuits Expected to Keep Growing

In October of 2010 the FDA approved Pradaxa for the prevention of blood clots and strokes in patients with atrial fibrillation (irregular heartbeat). It was marketed by its manufacturer, Boehringer Ingelheim, as an alternative to warfarin. Over the following year a number of cases of gastrointestinal bleeding were reported, some severe enough to cause death. According to the Cleveland Clinic, Pradaxa had a 33% increased risk of heart attack or heart disease over warfarin.

According to the Institute of ...

continue reading...

Doctor says blood thinner carries risks

In a column in the Spokesman-Review out of Washington, Dr. Anthony L. Komaroff, M.D., answers a letter-writer’s question about the blood-thinner Pradaxa.

The letter-writer says his wife has atrial fibrillation, and her medication was recently changed from warfarin to Pradaxa. He wants to know if she’s right in claiming that the medicine is just as effective, although it requires fewer tests.

Komaroff writes that technically, Pradaxa is just as effective in preventing blood clots. But Pradaxa presents some risks that warfarin, the ...

continue reading...

Blood thinner approval has competitors ‘on their toes’

A report on the blog FiercePharma says the approval of blood thinner Eliquis in Europe has the manufacturers of competing medications “on their toes.”

Eliquis, from Pfizer and Bristol-Myers Squibb, was developed as an alternative to warfarin, which for decades has been the standard treatment for blood clot prevention.

But according to FiercePharma, warfarin “comes with a host of dosage-tweaking rules, plus interactions with alcohol and food, so it is difficult for ...

continue reading...

FDA approves new blood thinner

The U.S. Food and Drug Administration has approved a new blood thinner manufactured by Pfizer Inc. and Bristol-Myers Squibb. A Bloomberg report describes Eliquis as a “potential blockbuster heart drug.”

The Food and Drug Administration cleared Eliquis for the prevention of blood clots that develop in patients with the heart rhythm disorder atrial fibrillation, after the manufacturers failed in two previous efforts to win approval for the drug.

It’s among a new ...

continue reading...

Blood thinner approved in Japan

Regulators in Japan have approved the blood thinner Eliquis, the Japan Daily Times reports.

Eliquis is the brand name for apixaban, manufactured by Bristol-Myers Squibb Co and Pfizer Inc. It’s among a new class of blood thinners meant to replace decades-old warfarin, which is effective but can be difficult to use because it requires dietary restrictions and frequent testing.

Pharmaceutical companies have been looking to warfarin alternatives as potentially profitable areas of ...

continue reading...
Page 2 of 5 12345